Clinical and genomic characterisation of a fatal Puumala orthohantavirus case with low levels of neutralising antibodies. Issue 10 (3rd October 2022)

• Record Type: Journal Article
• Authors: Tuiskunen Bäck, Anne; Rasmuson, Johan; Thunberg, Therese; Rankin, Gregory; Wigren Byström, Julia; Andersson, Charlotta; Sjödin, Andreas; Forsell, Mattias; Ahlm, Clas
• Is Part Of: Infectious diseases. Volume 54:Issue 10(2022)
• Page Start: 766
• Page End: 772
• Publication Date: 2022-10-03
• Subjects: Puumala orthohantavirus -- orthohantavirus -- virus sequence -- Icatibant -- neutralising antibodies -- viral load; Communicable diseases -- Periodicals; Communicable Diseases -- Periodicals; Communicable diseases; Periodicals; 616.9
• DOI: 10.1080/23744235.2022.2076904
• Languages: English
• ISSNs: 2374-4235

Abstract

Abstract: Background: Orthohantaviruses are rodent-borne emerging viruses that cause haemorrhagic fever with renal syndrome (HFRS) in Eurasia and hantavirus pulmonary syndrome in America. Transmission between humans have been reported and the case-fatality rate ranges from 0.4% to 40% depending on virus strain. There is no specific and efficient treatment for patients with severe HFRS. Here, we characterised a fatal case of HFRS and sequenced the causing Puumala orthohantavirus (PUUV). Methods: PUUV RNA and virus specific neutralising antibodies were quantified in plasma samples from the fatal case and other patients with non-fatal PUUV infection. To investigate if the causing PUUV strain was different from previously known strains, Sanger sequencing was performed directly from the patient's plasma. Biopsies obtained from autopsy were stained for immunohistochemistry. Results: The patient had approximately tenfold lower levels of PUUV neutralising antibodies and twice higher viral load than was normally seen for patients with less severe PUUV infection. We could demonstrate unique mutations in the S and M segments of the virus that could have had an impact on the severity of infection. Due to the severe course of infection, the patient was treated with the bradykinin receptor inhibitor icatibant to reduce bradykinin-mediated vessel permeability and maintain vascular circulation. Conclusions: Our data suggest that bradykinin receptor inhibitor may not be highly efficient to treat patients that are at an advanced stage of HFRS. Low neutralising antibodies and high viral load at admission to the hospital were associated with the fatal outcome and may be useful for future predictions of disease outcome.